Form S-3ASR Cabaletta Bio, Inc.

Go back to Form S-3ASR Cabaletta Bio, Inc.

Cabaletta Bio Inc. (CABA) PT Raised to $32 at Stifel

March 21, 2024 12:41 PM EDT

Stifel analyst Ben Burnett raised the price target on Cabaletta Bio Inc. (NASDAQ: CABA) to $32.00 (from $31.00) while maintaining a Buy rating.

The analyst comments "We like CABA's leading position in Myositis as this is a disease space where there isn't as much competition from... More

Cabaletta Bio (CABA) Files Mixed Shelf

March 21, 2024 8:04 AM EDT

Cabaletta Bio (NASDAQ: CABA) has filed mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Warrants

Units

... More